> Products
> By Supplier
> By AOI
> Library
> Search
> News
> Distributors
> Sign Up
> Contact Us
> Links
> Investor Relations


Areas of Investigation
>AutoImmune Disease
>Biogenic Amines
>Bone & Mineral Metabolism
>Cytokines & Adhesion Molecules
>Diabetes
>Endocrinology
>Growth
>Osteosite (IHC) Antibodies
>Instrumentation
>Inflammation & infection
>Neuroedocrinology
>Pre Clinical & Veterinary Studies
>Proteases & Inhibitors
>Tumour Markers
>Interferons
>Histology & Cytology Antibodies
>Antibodies
>Other BioChemicals
>Cartilage Metabolism

 
        
 

Investor Relations

 

* AIM Rule 26
* Company Profile
* Corporate Governance Statement
* Directors 

    

* Annual Report & Accounts (Year ended 31 March 2005)
* Unaudited Interim Results for the Six-Month Period to 30 September 2005)

* Annual Report and Accounts (Year ended 31 March 2006)
* Unaudited Interim Results for the Six-Month Period to 30 September 2006

* Annual Report and Accounts (Year ended 31st March 2007)
* Unaudited Interim Results for the Six-Month Period to 30 September 2007

  

Investors

* www.sitkapartners.com
* www.noblegp.com

         Current Share price and RNS Releases

      * Click Here        
 
   
Privacy Policy | Disclaimer |Copyright